间充质干细胞:细胞替代治疗肝硬化  

Mesenchymal stem cells:the cell replacement therapy for liver cirrhosis

作　　者：刘凤永[1] 王茂强[1] Liu Fengyong;Wang Maoqiang(Department of Interventional Radiology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心介入放射科,北京100853

出　　处：《中华肝胆外科杂志》2019年第4期308-311,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：国家自然科学基金面上项目(81671800);北京市自然科学基金面上项目(7172204)。

摘　　要：肝硬化是肝纤维化的晚期阶段,常引发致命性并发症,严重威胁人类健康。肝移植是目前治疗肝硬化的首选方法,但其治疗效果受多种因素限制。近几年,国内外研究者提出细胞替代治疗肝硬化的理念。其中,间充质干细胞(MSCs)具有来源广泛、抑制免疫、减少炎症浸润和促炎因子释放、可以经诱导分化为肝细胞等特点,是细胞替代治疗肝硬化的有效药物。本文对间充质干细胞的特点、治疗肝硬化的机制以及最新的实验研究和临床试验展开综述。Cirrhosis is an advanced stage of liver fibrosis that causes fatal complications and and threats human health.Liver transplantation is the preferred treatment method of cirrhosis patients,but the therapeutic effect of liver transplantation is limited.In recent years,researchers at home and abroad have proposed the concept of cell replacement therapy for liver cirrhosis.Among them,mesenchymal stem cells(MSCs)have a wide range of sources,the MSCs can inhibit immunity and reduce the infiltration of inflammatory cells and release of pro-inflammatory cytokines,and they can also be induced to differentiate into hepatocytes to mitigate fibrosis,which become the preferred drug of cell replacement therapy for cirrhosis.Here,we mainly reviewed the mesenchymal stem cells from the features,the mechanisms of treatment for cirrhosis,and recent experimental studies and clinical trials.

关 键 词：肝硬化 间充质干细胞 治疗结果 

分 类 号：R575.2[医药卫生—消化系统]